Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomea Fusion, Inc.

1.85
+0.01500.82%
Volume:645.78K
Turnover:1.22M
Market Cap:109.79M
PE:-0.62
High:1.95
Open:1.85
Low:1.83
Close:1.83
52wk High:13.07
52wk Low:1.29
Shares:59.51M
Float Shares:48.85M
Volume Ratio:1.89
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9937
EPS(LYR):-3.8339
ROE:-170.54%
ROA:-68.73%
PB:3.99
PE(LYR):-0.48

Loading ...

Company Profile

Company Name:
Biomea Fusion, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
63
Office Location:
1599 Industrial Road,San Carlos,California,United States
Zip Code:
94070
Fax:
- -
Introduction:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Directors

Name
Position
Michael J. M. Hitchcock
Interim Chief Executive Officer and Director
Eric Aguiar
Lead Independent Director
Rainer Erdtmann
President, Chief Operating Officer and Director
Elizabeth Faust
Director
Julianne Averill
Director
Sumita Ray
Director

Shareholders

Name
Position
Michael J. M. Hitchcock
Interim Chief Executive Officer and Director
Rainer Erdtmann
President, Chief Operating Officer and Director
Juan Pablo Frias
Chief Medical Officer and Head of Diabetes